ITOS241220C1000
- 0.00
- 0.000.00%
ITeos Therapeutics Newsroom
ITeos to Participate in Upcoming Investor Conferences
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
Leerink Partners Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
Strategic Catalysts and Financial Stability Underpin Buy Rating for ITeos Therapeutics
Express News | Iteos Therapeutics Inc : JP Morgan Cuts Target Price to $22 From $24
ITeos Therapeutics | 10-Q: Q3 2024 Earnings Report
ITeos Therapeutics Reports Q3 EPS ($1.05), Consensus (89c)
Express News | Iteos Therapeutics Inc Qtrly EPS $-1.05
Express News | ITeos Therapeutics Q3 2024 GAAP EPS $(1.05) Beats $(1.17) Estimate, Pro Forma Cash And Investment Balance Of $683.9M As Of September 30, 2024 Expected To Provide Runway Through 2027 Across A Number Of Impactful Portfolio Milestones
Express News | Iteos Therapeutics Inc: Sees Runway Through 2027
Express News | Iteos Reports Third Quarter 2024 Financial Results and Provides Business Updates
Express News | Iteos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 a2a-005 Clinical Trial Data in 2L Nsclc at Esmo Immuno-Oncology Congress
ITeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
We're Keeping An Eye On ITeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate
ITeos Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Market-Moving News for September 16th
ITeos Therapeutics Analyst Ratings